Reported Sunday, Regeneron Pharmaceuticals Presented Pivotal Data On Linvoseltamab At AACR 2024, Reinforcing A High Response Rate That Deepens Over Time In Patients With Heavily Pre-Treated Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals presented pivotal data on Linvoseltamab at AACR 2024, showing a high response rate in heavily pre-treated multiple myeloma patients. The study with 117 patients showed a 71% objective response rate, with significant percentages achieving complete responses or very good partial responses. The median duration of response, progression-free survival, and overall survival were not reached, indicating promising outcomes. Among patients with a complete response, 93% were minimum residual disease negative.
April 08, 2024 | 6:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals presented strong data on Linvoseltamab for multiple myeloma at AACR 2024, indicating a high response rate and promising patient outcomes.
The positive data presented by Regeneron Pharmaceuticals on Linvoseltamab at AACR 2024, showing a high response rate and promising outcomes in heavily pre-treated multiple myeloma patients, is likely to be viewed positively by investors. The detailed results, including a 71% objective response rate and high rates of complete response, suggest the potential for Linvoseltamab to become a significant treatment option. This could lead to increased investor confidence in Regeneron's pipeline and potentially boost the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90